Novel inhibitors of MAP4K4 (HGK), an acute therapy to prevent cardiac muscle cell death following myocardial infarction (360G-Wellcome-106328_Z_14_D)
Heart disease is the most frequent source of death and disability worldwide, most especially as heart attacks (cardiac muscle cell death from obstructed blood flow to the heart). Its severity is due in part to heart muscle's inability to rebuild itself as most other tissues can. One potential strategy, to enhance standard therapies like “clot-busting” drugs and stents, is to suppress cell death directly by protecting the injured, jeopardized muscle cells. Professor Michael Schneider at Imperial College London has identified the enzyme MAP4K4 as a key regulator of cardiac cell death and has devised novel, potent, selective drug-like inhibitors to protect human cardiac muscle grown in the laboratory. This Seeding Drug Discovery Award will enable the innovative use of human cardiac muscle grown from stem cells to pinpoint the molecules responsible for cardiac injury and will take the programme of research the essential steps further, towards the development of MAP4K4 inhibitors as clinically workable compounds.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 100000 |
Applicant Surname | Schneider |
Approval Committee | Seeding Drug Discovery Committee |
Award Date | 2017-10-01T00:00:00+00:00 |
Financial Year | 2017/18 |
Grant Programme: Title | Seeding Drug Discovery Award |
Internal ID | 106328/Z/14/D |
Lead Applicant | Prof Michael Schneider |
Partnership Value | 100000 |
Planned Dates: End Date | 2017-07-02T00:00:00+00:00 |
Planned Dates: Start Date | 2017-06-30T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |